Efficacy and resistance

The regulatory approval of GENVOYA®▼ (elvitegravir / cobicistat / emtricitabine /
tenofovir alafenamide)
is based on the results from six phase 2/3 studies in various HIV-positive populations: treatment-naïve adults, virologically suppressed adults, and adults with renal impairment and children.1